GCM
HZNP

Glaxis Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Glaxis Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,000
Closed -$526K – 41
2022
Q1 		$526K Buy
+5,000
New +$487K 0.74% 23

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Glaxis Capital Management's HZNP Position: Q2 2022 in Review

Glaxis Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2022, closing a stake of 5,000 shares — an estimated $526K sold.

Glaxis Capital Management first reported a position in HZNP in Q1 2022 and held it in 1 quarter. The position peaked at $526K in Q1 2022. 616 funds tracked by Wall St. Rank hold HZNP as of Q2 2022.

  • Glaxis Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2022 after selling out during the quarter.
  • Glaxis Capital Management sold 5,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2022, an estimated $526K.
  • Glaxis Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2022 and held it in 1 quarter.
  • Glaxis Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $526K in Q1 2022.
  • 616 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2022.

Based on Glaxis Capital Management's 13F filing for Q2 2022, filed 10 Aug 2022.